JOURNAL OF CONTROLLED RELEASE

Scope & Guideline

Pioneering the future of controlled release technologies.

Introduction

Welcome to your portal for understanding JOURNAL OF CONTROLLED RELEASE, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0168-3659
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1984 to 2024
AbbreviationJ CONTROL RELEASE / J. Control. Release
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The Journal of Controlled Release focuses on the development and application of advanced drug delivery systems and nanomedicines. Its core research areas encompass a wide array of methodologies aimed at optimizing the therapeutic efficacy and safety of drugs through controlled release mechanisms.
  1. Drug Delivery Systems:
    Research on various drug delivery systems including nanoparticles, liposomes, hydrogels, and microneedles designed to improve the bioavailability and efficacy of therapeutic agents.
  2. Nanomedicine:
    Exploration of nanotechnology applications in medicine, focusing on the design, synthesis, and evaluation of nanomaterials for targeted drug delivery and therapy.
  3. Therapeutic Formulations:
    Development of innovative formulations that enhance the delivery and release profiles of drugs, including responsive systems that react to specific biological stimuli.
  4. Biomaterials Engineering:
    Investigation of biocompatible materials for drug delivery systems, emphasizing the interaction between drugs and the biological environment to optimize therapeutic outcomes.
  5. Clinical Applications:
    Translation of laboratory findings to clinical settings, assessing the safety and efficacy of new drug delivery technologies in various therapeutic areas.
  6. Immunotherapy:
    Integration of drug delivery systems with immunotherapeutic strategies to enhance the immune response against cancer and other diseases.
The Journal of Controlled Release is witnessing exciting trends and emerging themes that reflect the evolving landscape of drug delivery research. These areas are gaining traction and are likely to shape the future of the field.
  1. Stimuli-Responsive Drug Delivery:
    Research on drug delivery systems that respond to specific stimuli (e.g., pH, temperature, or light) is increasing, enabling more precise control over drug release profiles.
  2. Extracellular Vesicles (EVs):
    The use of EVs as drug delivery vehicles is gaining prominence, leveraging their natural ability to facilitate cellular uptake and modulate immune responses.
  3. CRISPR and Gene Editing Technologies:
    The integration of CRISPR and other gene editing technologies into drug delivery systems is emerging as a powerful approach for targeted genetic therapies.
  4. Nanomaterials for Cancer Therapy:
    Innovative nanomaterials designed for cancer therapy, including those that enhance immunogenicity and target the tumor microenvironment, are rapidly advancing.
  5. Personalized Medicine Approaches:
    The shift towards personalized medicine is reflected in research aimed at tailoring drug delivery systems to individual patient needs, improving treatment outcomes.
  6. Combination Therapies:
    There is a growing trend in combining different therapeutic modalities (e.g., chemotherapy and immunotherapy) within a single delivery system to enhance therapeutic efficacy.

Declining or Waning

While the Journal of Controlled Release has maintained a strong focus on drug delivery and nanomedicine, certain areas have seen a decline in research output. These waning scopes may reflect shifting interests within the scientific community or advancements in alternative methodologies.
  1. Conventional Drug Delivery Methods:
    There is a noticeable decline in research focused on traditional drug delivery methods as the field shifts towards more innovative approaches like nanotechnology and personalized medicine.
  2. Non-targeted Drug Delivery:
    Research on non-targeted delivery systems is decreasing as there is a growing emphasis on targeted therapies that improve specificity and reduce side effects.
  3. Passive Release Mechanisms:
    Studies exploring passive release mechanisms are becoming less common, with a trend towards developing stimuli-responsive systems that offer more control over drug release.
  4. Single-Modal Therapies:
    The exploration of single-modal therapies is waning as there is a shift towards combination therapies that integrate multiple modalities for enhanced efficacy.
  5. In vitro Models:
    There is a reduction in the use of basic in vitro models for drug testing, with more research focusing on complex in vivo models that better mimic human physiology.

Similar Journals

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Exploring the Frontiers of Drug Development
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

AAPS Journal

Exploring New Frontiers in Pharmacology and Toxicology.
Publisher: SPRINGERISSN: 1550-7416Frequency: 1 issue/year

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Advanced Pharmaceutical Bulletin

Unveiling Innovative Discoveries in Pharmacology and Toxicology
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS

Advancing the Frontiers of Biomaterials Innovation
Publisher: WILEYISSN: 1552-4973Frequency: 8 issues/year

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, published by Wiley, is a leading journal in the field of biomaterials and biomedical engineering, with an impact factor reflected in its relevant Scopus rankings—including a Q2 position in Biomedical Engineering and Q3 in Biomaterials for 2023. This journal, with ISSN 1552-4973 and E-ISSN 1552-4981, serves as a vital platform for disseminating pioneering research and innovative applications of biomaterials. Positioned in the United States, it aims to bridge the gap between material science and biological applications, fostering collaboration among researchers, professionals, and students dedicated to advancing technology in healthcare. With a convergence of studies from 2003 to 2024 and a growing focus on open access, the journal ensures greater visibility and accessibility for groundbreaking research. Join us in exploring the dynamic field of biomaterials, as we push the boundaries of science and engineering for improved patient outcomes.

Materials Science & Engineering C-Materials for Biological Applications

Connecting materials science with biological advancements.
Publisher: ELSEVIERISSN: 0928-4931Frequency: 12 issues/year

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Journal of Reports in Pharmaceutical Sciences

Innovating Drug Development Through Groundbreaking Research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

ADVANCED DRUG DELIVERY REVIEWS

Transforming Pharmaceutical Frontiers.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Drug Delivery and Translational Research

Advancing Pharmaceutical Sciences through Translational Insights.
Publisher: SPRINGER HEIDELBERGISSN: 2190-393XFrequency: 12 issues/year

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Connecting scholars to tackle health challenges in the tropics.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

BIOMATERIALS

Elevating Knowledge in the Interdisciplinary World of Biomaterials
Publisher: ELSEVIER SCI LTDISSN: 0142-9612Frequency: 36 issues/year

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.